1.The influence of treating course on the Hpid-regulating effect of Xuezhikang and Simvastati
Qiuye TENG ; Zhaoli TANG ; Biyun QIN ; Zhikun ZHANG ; Hailian TANG ; Haiyu CHENG
Clinical Medicine of China 2011;27(9):910-913
ObjectiveTo observe the influence of treating course on the lipid-regulating effect of Xuezhikang and Simvastati.MethodsTwo hundred and two patients with unstable angina pectoris(UAP) were randomly enrolled and divided into Simvastatin group(n = 98)and Xuezhikang group(n = 104).The TC, TG,LDL-C, HDL-Clevelsweremeasuredbeforethe treatment and atthe3rd, 6thmonthafter the treatment.According to the suitable threshold of blood lipids in normal Chinese people, the patients who had abnormal blood lipids were picked out from the two groups for the further observation.ResultsThe lipidregulating effects of Simvastatin and Xuezhikang were showed up at the 3rd month, and the effective rate were 40.6% and 60.9% for TC regulation,51.2% and 84.5% for LDL-C regulation,22.2% and 61.5% for HDL-C regulation.We found significantly better effects of Xuezhikang than that of Simvastatin(x2 = 6.38,17.05,4.04;P < 0.05, P < 0.01, P < 0.05) .However, at the 6th month the effective rate of Simvastatin and Xuezhikang were 89.9% and 95.4% for TC regulation,89.1% and 97.2% for LDL-C regulation,83.3% and 84.6% for HDL-C regulation, which showed no significant differences (x2 = 1.81,3.57, 0.01 ; Ps > 0.05).The effective percentages of reduced TG level of Simvastatin and Xuezhikang were 9.5% and 24.5% at the 3rd month,51.4% and 68.4% at the 6th month, which showed significant differences (x2 = 6.45,5.13 ; Ps < 0.05) between the two groups at both time points.Conclusion The lipid-regulating effects of Xuezhikang and Simvastati were influenced by the treating period.Xuezhikang shows lipid-regulating effect more quickly ,and it is recommended in treating CHD patients,especially for the patients with hypertriglyceridemia.
2.Clinical application of radical cystectomy with orthotopic ileal neobladder
Jisan WANG ; Lei SU ; Zhaoli TENG ; Shide SONG ; Bo DING ; Yongzhang SHEN
Chinese Journal of Primary Medicine and Pharmacy 2008;15(10):1615-1616
Objective To evaluate the clinical efficacy of radical cystectomy with orthotopic ileal neobled-der. Methods 28 cases of bladder tumor treated with radical cystectomy with ileal orthotopic neobladder were studiedretrospectively. Results All patients achieved excellent continence,whereas possessory patients needed time-lapse e-mietion at nighttime. The mean bladder capacity for the entire group was 330 ml. Residual urine was less than 70 ml.All of these patients have been followed up for 4~58 months with a mean of 18 months. They were survival with no re-currences except 1 case. Good urinary stream was reported. A little operative complications occurred. ConclusionThe operation of radical cystectomy with orthotopic ileal neobladder might be an ideal way of bladder replacement,characterized by large capacity,low pressure, orthotopie continent urination.
3.The Positive Association between Subclinical Hypothyroidism and Newly-Diagnosed Hypertension Is More Explicit in Female Individuals Younger than 65
Xichang WANG ; Haoyu WANG ; Li YAN ; Lihui YANG ; Yuanming XUE ; Jing YANG ; Yongli YAO ; Xulei TANG ; Nanwei TONG ; Guixia WANG ; Jinan ZHANG ; Youmin WANG ; Jianming BA ; Bing CHEN ; Jianling DU ; Lanjie HE ; Xiaoyang LAI ; Yanbo LI ; Zhaoli YAN ; Eryuan LIAO ; Chao LIU ; Libin LIU ; Guijun QIN ; Yingfen QIN ; Huibiao QUAN ; Bingyin SHI ; Hui SUN ; Zhen YE ; Qiao ZHANG ; Lihui ZHANG ; Jun ZHU ; Mei ZHU ; Yongze LI ; Weiping TENG ; Zhongyan SHAN
Endocrinology and Metabolism 2021;36(4):778-789
Background:
Subclinical hypothyroidism (SCH) is the most common thyroid dysfunction, and its relationship with blood pressure (BP) has been controversial. The aim of the study was to analyze the association between SCH and newly-diagnosed hypertension.
Methods:
Based on data from the Thyroid disease, Iodine nutrition and Diabetes Epidemiology (TIDE) study, 49,433 euthyroid individuals and 7,719 SCH patients aged ≥18 years were enrolled. Patients with a history of hypertension or thyroid disease were excluded. SCH was determined by manufacturer reference range. Overall hypertension and stage 1 and 2 hypertension were diagnosed according to the guidelines issued by the American College of Cardiology/American Heart Association in 2017.
Results:
The prevalence of overall hypertension (48.7%), including stage 1 (28.9%) and 2 (19.8%) hypertension, increased significantly in SCH patients compared with euthyroid subjects. With elevated serum thyroid stimulating hormone (TSH) level, the hypertension prevalence also increased significantly from the euthyroid to different SCH subgroups, which was more profound in females or subjects aged <65 years. The age- and sex-specific regression analysis further demonstrated the same trends in the general population and in the 1:1 propensity matched population. Similarly, several BP components (i.e., systolic, diastolic, and mean arterial BP) were positively associated with TSH elevation, and regression analysis also confirmed that all BP components were closely related with SCH in female subjects aged <65 years.
Conclusion
The prevalence of hypertension increases for patients with SCH. SCH tends to be associated with hypertension and BP components in females younger than 65 years.
4.The Positive Association between Subclinical Hypothyroidism and Newly-Diagnosed Hypertension Is More Explicit in Female Individuals Younger than 65
Xichang WANG ; Haoyu WANG ; Li YAN ; Lihui YANG ; Yuanming XUE ; Jing YANG ; Yongli YAO ; Xulei TANG ; Nanwei TONG ; Guixia WANG ; Jinan ZHANG ; Youmin WANG ; Jianming BA ; Bing CHEN ; Jianling DU ; Lanjie HE ; Xiaoyang LAI ; Yanbo LI ; Zhaoli YAN ; Eryuan LIAO ; Chao LIU ; Libin LIU ; Guijun QIN ; Yingfen QIN ; Huibiao QUAN ; Bingyin SHI ; Hui SUN ; Zhen YE ; Qiao ZHANG ; Lihui ZHANG ; Jun ZHU ; Mei ZHU ; Yongze LI ; Weiping TENG ; Zhongyan SHAN
Endocrinology and Metabolism 2021;36(4):778-789
Background:
Subclinical hypothyroidism (SCH) is the most common thyroid dysfunction, and its relationship with blood pressure (BP) has been controversial. The aim of the study was to analyze the association between SCH and newly-diagnosed hypertension.
Methods:
Based on data from the Thyroid disease, Iodine nutrition and Diabetes Epidemiology (TIDE) study, 49,433 euthyroid individuals and 7,719 SCH patients aged ≥18 years were enrolled. Patients with a history of hypertension or thyroid disease were excluded. SCH was determined by manufacturer reference range. Overall hypertension and stage 1 and 2 hypertension were diagnosed according to the guidelines issued by the American College of Cardiology/American Heart Association in 2017.
Results:
The prevalence of overall hypertension (48.7%), including stage 1 (28.9%) and 2 (19.8%) hypertension, increased significantly in SCH patients compared with euthyroid subjects. With elevated serum thyroid stimulating hormone (TSH) level, the hypertension prevalence also increased significantly from the euthyroid to different SCH subgroups, which was more profound in females or subjects aged <65 years. The age- and sex-specific regression analysis further demonstrated the same trends in the general population and in the 1:1 propensity matched population. Similarly, several BP components (i.e., systolic, diastolic, and mean arterial BP) were positively associated with TSH elevation, and regression analysis also confirmed that all BP components were closely related with SCH in female subjects aged <65 years.
Conclusion
The prevalence of hypertension increases for patients with SCH. SCH tends to be associated with hypertension and BP components in females younger than 65 years.